For instance, patients with both CRSwNP and asthma may benefit more from dupilumab as several studies have demonstrated its superior efficacy in managing both nasal and lower respiratory symptoms when compared to anti-IgE or anti-IL-5 therapies, which often show inadequate upper airway control [14,15]. The gene discussed is IGHE; the disease is asthma.